Mills, Catherine M Turner, Jonathan Piña, Ivett C Garrabrant, Kathleen A Geerts, Dirk Bachmann, André S Peterson, Yuri K Woster, Patrick M
Published in
European journal of medicinal chemistry
The epigenetic regulator lysine specific demethylase 1 (LSD1), a MYCN cofactor, cooperatively silences MYCN suppressor genes. Furthermore, LSD1 has been correlated with adverse effects in neuroblastic tumors by propagating an undifferentiated, malignant phenotype. We observed that high LSD1 mRNA expression in MYCN-expressing neuroblastoma (NB) corr...
Khoei, Samin Boustani, Mohammad Reza Pak, Neda
Published in
BMC neurology
As the third most common malignancy of childhood, Neuroblastoma has a great propensity to metastasize to multiple organs. The most common site of metastasis is the bone and bone marrow. Concerning the central nervous system, neuroblastoma usually involves the calvarium and the external dural surface. The skull metastases may show different appearan...
Kambe, Kosuke Iguchi, Masafumi Higashi, Mayumi Yagyu, Shigeki Fumino, Shigehisa Kishida, Tsunao Mazda, Osam Tajiri, Tatsuro
Published in
Pediatric surgery international
Mouse IgG anti-disialoganglioside GD2 antibody-secreting mouse mesenchymal stem cells (anti-GD2-MSCs) were developed, and their anti-tumor effects were validated in an in vivo neuroblastoma mouse model. Anti-GD2 antibody constructs were generated, incorporating FLAG-tagged single-chain fragment variables against GD2 fused to a linker sequence, and ...
Bonfiglio, Ferdinando Lasorsa, Vito Alessandro Cantalupo, Sueva D'Alterio, Giuseppe Aievola, Vincenzo Boccia, Angelo Ardito, Martina Furini, Simone Renieri, Alessandra Morini, Martina
...
Published in
EBioMedicine
Neuroblastoma (NB) is the most common solid extracranial paediatric tumour. Genome-wide association studies have driven the discovery of common risk variants, but no large study has investigated the contribution of rare variants to NB susceptibility. Here, we conducted a whole-exome sequencing (WES) of 664 NB cases and 822 controls and used indepen...
Ghosh, Adarsh Yekeler, Ensar Dalal, Deepa Holroyd, Alexandria States, Lisa
Published in
European radiology
To determine the role of apparent diffusion coefficient (ADC) histogram analysis in the identification of MYCN-amplification status in neuroblastomas. We retrospectively evaluated imaging records from 62 patients with neuroblastomas (median age: 15 months (interquartile range (IQR): 7-24 months); 38 females) who underwent magnetic resonance imaging...
Liang, Ying Wang, Qionglin Zhang, Xianwei Zhang, Mengxin Du, Bang Cheng, Weyland Wang, Huanmin Li, Lifeng Hou, Guangjun Zhang, Wancun
...
Published in
Analytical biochemistry
A dual isothermal amplification assay with dual fluorescence signal detection strategy, named dual isothermal amplification all-in-one approach, was developed for rapid, one-step, highly sensitive quantification of plasma circulating MYCN copy number of neuroblastoma (NB). The developed strategy consisted of rolling circle amplification (RCA) and l...
Pauwels, Elin; Celen, Sofie; 45321; Baete, Kristof; 34780; Koole, Michel; 54596; Bechter, Oliver; 84395; Bex, Marie; Renard, Marleen; Clement, Paul M; 41136; Jentjens, Sander; Serdons, Kim;
...
PURPOSE: Despite its limitations, [123I]MIBG scintigraphy has been the standard for human norepinephrine transporter (hNET) imaging for several decades. Recently, [18F]MFBG has emerged as a promising PET alternative. This prospective trial aimed to evaluate safety, biodistribution, tumour lesion pharmacokinetics, and lesion targeting of [18F]MFBG a...
Pauwels, Elin Celen, Sofie Baete, Kristof Koole, Michel Bechter, Oliver Bex, Marie Renard, Marleen Clement, Paul M Jentjens, Sander Serdons, Kim
...
Published in
European journal of nuclear medicine and molecular imaging
Despite its limitations, [123I]MIBG scintigraphy has been the standard for human norepinephrine transporter (hNET) imaging for several decades. Recently, [18F]MFBG has emerged as a promising PET alternative. This prospective trial aimed to evaluate safety, biodistribution, tumour lesion pharmacokinetics, and lesion targeting of [18F]MFBG and perfor...
Li, Xiang Yang, Feili He, Na Zhang, Ming Lv, Yan Yu, Yue Dong, Qian Hou, Xiaofu Hao, Yanbing An, Zhida
...
Published in
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Amplification of the MYCN gene (MNA) is observed in approximately 25% to 35% of neuroblastoma patients, and is a well-recognized marker of tumor aggressiveness and poor outcomes. Targeting MYCN is a novel therapy strategy to induce tumor regression. Here, we discovered that a BIRC5/Survivin inhibitor, YM155, specifically inhibits MNA neuroblastoma ...
Wang, Hao Shi, Bozhong Zhang, Xiaoyang Shen, Ping He, Qiao Yin, Minzhi Pan, Yi Ma, Jing
Published in
Pathology, research and practice
Neuroblastoma (NB) is a sympathetic nervous system tumor and one of the most common pediatric, extra-cranial, solid tumors, especially in early childhood. Its expression is heterogeneous and shows a unique clinical and prognostic feature. Due to its insidious onset, most diagnoses are accompanied by metastasis, making patient prognoses extremely po...
